The GI-Map test provides an acccurate resource for effective clinical diagnosis. In the last few decades, DNA analysis has transformed the field of microbiology. In the USA, the National Institutes of Health have followed suit with initiatives such as the Human Microbiome Project, which characterised the microbiome from over 15 habitats of the body in more than 200 healthy human subjects using DNA analysis.
More than ever before, clinicians are keenly aware of the health benefits or disease risks brought about by the microorganisms that inhabit the human body. Culture techniques that were previously the standard, left up to 50% of bacterial species virtually invisible.
When next-generation methods revolutionised this field, it allowed the identification of tremendous numbers of previously unknown organisms. Anaerobic bacteria make up a large part of the human microbiome and can be opportunistic and cause illness. Therefore, inability to cultivate these organisms left a large blind spot for clinicians when trying to diagnose the source of infection.
This specialised stool test works efficiently to screen the body for ‘synergistic’ and pathogenic bacteria, parasites, fungi, pathogens, and viruses – all of which may have a negative impact on the body and overall health if they are out of balance.
The GI-Map takes the guesswork out of many aspects of diagnosis so that the practitioner can formulate an effective treatment plan for clients. The test is used to determine if there are certain pathogenic organisms within the body that might cause illnesses like autoimmune problems, arthritis, and most chronic conditions that can be impacted by the gut bacteria.
The Gastrointestinal Microbial Assay Plus (GI-MAP) is designed to assess a patient’s microbiome from a single stool sample, with particular attention to microbes that may be disturbing normal microbial balance and may contribute to perturbations in the gastrointestinal (GI) flora or illness. The panel is a comprehensive collection of microbial targets as well as immune and digestive markers. It screens for pathogenic bacteria, commensal bacteria, opportunistic pathogens, fungi, viruses, and parasites.
The GI-MAP primarily uses multiplex, automated, DNA analysis to give integrative and functional medicine practitioners a better view into the gastrointestinal microbiome.
GI-MAP test results support with diagnosis and clinical insights:
The GI-MAP (GI-Microbial Assay Plus) quantitatively assesses a patient’s microbiome with attention to bacterial, parasitic, and viral pathogens that can cause disease, disrupt the normal microbial balance, and contribute to chronic GI illness.
Diagnostic Solutions Laboratory utilises PCR technology with high sensitivity and specificity to provide quantitative, accurate, and reliable results.
The GI-MAP measures pathogenic organisms that can cause hospital-acquired infections (HAI) such as C. difficile or norovirus, foodborne illness such as E.coli or Salmonella, and common causes of diarrhoea such as Campylobacter, Shigella, and rotavirus A.
This panel also measures viral causes of gastroenteritis, unavailable by other common stool tests. It measures parasites such as Cryptosporidium, Giardia, and Entamoeba histolytica. The GI-MAP analyzes Helicobacter pylori and its virulence factors. It can detect opportunistic pathogens such as Pseudomonas aeruginosa, Klebsiella pneumoniae, Yersinia enterocolitica, and Proteus mirabilus, associated with autoimmune molecular mimicry.
Also included in the panel, it includes single-celled, amebic parasites such as Blastocystis hominis, Dientamoeba fragilis, and Entamoeba coli.
Fungal organisms are measured by the GI-MAP such as Candida, Geotrichum, and Microsporidia, with the latter being a new addition to DNA stool analysis.
Finally, the GI-MAP measures standard markers of immunity, inflammation and digestion including lactoferrin, secretory immunoglobulin A (sIgA), anti-gliadin antibody, and pancreatic elastase.
Diagnostic Solutions Laboratory has partnered with Designs for Health to bring practitioners in Australia and New Zealand these powerful advances in microbial testing. Their commitment to laboratory medicine uses proven methodologies that are accurate and reliable. This technology has high sensitivity, specificity and a rapid turnaround.
The GI pathogens include bacteria, parasites and viruses. Continuing with this platform, the GI-MAP measures opportunistic organisms, normal flora, fungi, parasites and antibiotic resistance genes.
Additionally, the Plus refers to immunologic markers for GI health and function including SIgA, Elastase, Calprotectin and Anti-gliadin testing.
Source: GI-MAP White paper: https://designsforhealth.com.au/wp-content/uploads/2018/09/Designs-For-Health-GI-MAP-White-Paper.pdf
Learn about the clinical applications and the research behind this new DNA/PCR stool test.
Presented by Dr David Brady, Chief Medical Officer for Diagnostic Solutions Laboratories and Dr Oscar Coetzee, Doctor of Clinical Nutrition and Associate Professor.